Virus News and Research

Latest Virus News and Research

Experimental Ebola virus vaccine protects cynomolgus macaques against current EBOV outbreak strain

National Institutes of Health scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona, when given at least seven days before exposure, and partially protects them if given three days prior.

7 Aug 2015

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

An urban emergency department that set up a hepatitis C testing protocol saw high rates of infection among intravenous drug users and Baby Boomers, with three-quarters of those testing positive unaware they were infected.

7 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

Children increase parents’ risk for viral infection

The BIG LoVE (Utah Better Identification of Germs-Longitudinal Viral Epidemiology) study, led by scientists at the University of Utah School of Medicine, finds that each bundle of joy puts the entire household at increased risk for infection with viruses that cause colds, flu, and other respiratory illnesses.

5 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

University of Liverpool study finds that HIV can continue to grow in patients despite treatment

HIV can continue to grow in patients who are thought to be responding well to treatment, according to research by the University of Liverpool.

5 Aug 2015

IP10 levels linked to HBsAg decline during TDF treatment

Baseline serum interferon-inducible protein 10 levels predict hepatitis B surface antigen reduction in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection treated with tenofovir disoproxil fumarate, findings indicate.

4 Aug 2015

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

Hepatitis B surface antigen level and platelet count at baseline are significantly associated with spontaneous HBsAg seroclearance in hepatitis B virus carriers and those with chronic infection, research suggests.

4 Aug 2015

Genotype A HBV mapped in acute, chronic Japanese patients

Not only is genotype A the most common genotype among Japanese patients with acute hepatitis B virus infection, but its prevalence is spreading among young adults with chronic HBV infection, shows a nationwide study.

4 Aug 2015

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time.

4 Aug 2015

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

4 Aug 2015

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.

4 Aug 2015

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases.

4 Aug 2015

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

3 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

First large field trial shows VSV-ZEBOV is effective against Ebola

A vaccine against the Ebola virus, tested in West Africa for the first time in a field trial, has proved to be effective. People who had come into close contact with someone recently infected, and who are therefore at particularly high risk, were vaccinated.

3 Aug 2015

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Tests of the experimental Ebola vaccine VSV-ZEBOV in over 7500 participants in Guinea suggest that the vaccine provides high protection against the disease as early as ten days after vaccination, in adults who have potentially been exposed to the virus by coming in close contact with a recently infected person.

31 Jul 2015

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola.

31 Jul 2015

Researchers reconstruct ancient virus to improve gene therapy

Researchers at Massachusetts Eye and Ear/Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina. This discovery, published July 30 in Cell Reports, could potentially be used to design gene therapies that are not only safer and more potent than therapies currently available, but may also help a greater number of patients.

31 Jul 2015

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body's microbiome.

31 Jul 2015

Virus News and Research

Latest Virus News and Research

Experimental Ebola virus vaccine protects cynomolgus macaques against current EBOV outbreak strain

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Children increase parents’ risk for viral infection

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

University of Liverpool study finds that HIV can continue to grow in patients despite treatment

IP10 levels linked to HBsAg decline during TDF treatment

Baseline HBsAg, platelet count predict spontaneous HBsAg seroclearance

Genotype A HBV mapped in acute, chronic Japanese patients

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Penn Medicine devises new approach to develop vaccines against lethal diseases

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Shire acquires Foresight Biotherapeutics for $300 million

First large field trial shows VSV-ZEBOV is effective against Ebola

Tests show VSV-ZEBOV vaccine safe and effective against Ebola

Guinea Phase III trial shows VSV-EBOV vaccine highly effective against Ebola

Researchers reconstruct ancient virus to improve gene therapy

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

A new way of characterising biomolecules eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in